Nonisotopic immunoassay with antibodies

Nonisotopic Immunoassay with Monoclonal or Clonotype Antibody. 91... 

In fact, most RIAs and many nonisotopic immunoassays use a competitive binding format (see Fig. 2). In this approach, the analyte in the sample to be measured competes with a known amount of added analyte that has been labeled with an indicator that binds to the immobilized antibody. After reaction, the free analyte—analyte-indicator solution is washed away from the soHd phase. The analyte-indicator on the soHd phase or remaining in the wash solution is then used to quantify the amount of analyte present in the sample as measured against a control assay using only an analyte-indicator. This is done by quantifying the analyte-indicator using the method appropriate for the assay, for example, enzyme activity, fluorescence, radioactivity, etc. 

The essential criteria for a useful analytical technique are specificity, sensitivity, accuracy, precision, simplicity, rapidity, economy, wide applicability, and freedom from hazard. It is well known that radioimmunoassay (RIA) was developed in 1959 by Yalow and Berson (Yl). Since then the radioimmunoassay method has been widely used in the field of clinical chemistry. Radioimmunoassay has inherent in it the advantages listed above. However, this method always requires special facilities for use and disposal of radioisotopes and consideration must be given to the fact that the labeled substances have short half-lives. Immunoassay methods are explosively increasing in use and development as an analytic technique in basic science as well as in clinical laboratory medicine (L1-L3, VI). With these points as background, efforts have been made to develop nonisotopic immunoassay methods or alternative immunoassay methods that are based on antigen-antibody reactions but do not involve use of a radioisotope. 

Immunoassays employing antibodies are widely used to quantify hormones (see Chapter 9). Currently, labeled-antibody (immunometric) assays with nonisotopic labels are the method of choice for measuring most hormones, especially peptides and proteins. Immunometric assays use saturating concentrations of two or more antibodies (often... 

The analytical detection limits of competitive and noncompetitive immunoassays are determined principally by the affinity of the antibody and the detection limit of the label used, respectively. Calculations have indicated that a lower limit of detection of lOfmol/L (Le., 600,000 molecules of analyte in a typical sample volume of 100 jiL) is possible in a competitive assay using an antibody with an affinity of iO L/mol. Table 9-2 illustrates the detection limits for isotopic and nonisotopic labels. A radioactive label, such as l, has low specific activity (7.5 million labels necessary for detection of 1 disintegration/s) compared with enzyme labels and chemiluminescent and fluorescent labels. Enzyme labels provide an amplification (each enzyme label produces many detectable product molecules), and the detection limit for an enzyme can be improved by replacing the conventional photometric detection reaction by a chemiluminescent or bioluminescent reaction. The combination of amplification and an ultrasensitive detection reaction makes noncompetitive chemiluminescent EIAs among the most sensitive types of immunoassay. Fluorescent labels also have... 

Immunoassays are used to measure PSA and are commercially available. Most of them use nonisotopic labels, such as enzyme, fluorescence, or chemiluminescence. The majority of these assays are automated on an immunoassay system. Different assays and even the same assay with different lots of reagent may produce different results. The reasons for such differences are due to changes in assay calibration, production lot variation, assay reaction time, reagent matrices, assay sensitivity, and imprecision. Antibodies react with different PSA epitopes therefore, some antibodies react dissimilarly with the various molecular forms of PSA. Assays are classified as equimolar if they bind to free and cPSA equally and nonequimolar if they bind to free or cPSA differently. Examples of equunolar assays are the ACCESS... 

A nonisotopic ELISA method in which serum specimens are added to microtiter wells coated with human Tg is also available. In this method, antibody binding is assessed using a peroxidase-conjugated anti-IgG/o-phenylenedi-amine system. An automated two-step fluorescent enzyme immunoassay has been reported. In this assay, Tg is immobilized on magnetic beads, and anti-human IgG mouse monoclonal antibody is labeled with alkafine phosphatase 4-methyiumbelliferyl phosphate is used as the substrate. IRMA and ELISA both have similar detection limits (approximately 3 to 5 U/mL). A considerably more sensitive radioassay has been reported in which diluted serum is incubated with T-labeled Tg to allow formation of antigen-antibody complexes these complexes are then precipitated by adding solid-phase protein A. Its detection limit is reported to be approximately 0.2 U/mL. 

The immunometric-type assay has also been adapted for use with nonisotopic labels and is typically carried out in a heterogeneous format in which the antibody is immobilized on a solid support, such as a microtiter dish, membrane, or collection of beads. The canonical clinical immunoassay format in toady s laboratories is the enzyme-linked immunosorbent sandwich assay, which employs two antibodies, one to capture the analyte and the other to detect and quantify it. More details of the principles of these and other immunoassay techniques are given elsewhere in this encyclopedia. 

In RIAs, a radioactive label is used for detection of the formation of an antibody -antigen complex. Thus, a simple, specific, sensitive, and precise determination of the radioactive isotope is available. At present, however, immunoassays are increasingly carried out with nonisotopically labeled antigens or antibodies because of the legal restrictions on the use of radioactive material. 

---